Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zaleplon
Drug ID BADD_D02379
Description Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Indications and Usage For the treatment of short-term treatment of insomnia in adults.
Marketing Status approved; illicit; investigational
ATC Code N05CF03
DrugBank ID DB00962
KEGG ID D00530
MeSH ID C085665
PubChem ID 5719
TTD Drug ID D09DWL
NDC Product Code 29300-131; 71335-1054; 71335-1387; 43063-783; 57237-239; 42043-210; 57237-240; 68788-7208; 53296-0056; 65862-215; 71335-0236; 0054-0085; 63629-3405; 65862-214; 16436-0056; 42043-211; 0054-0084; 71335-1466; 51846-1026; 65862-197; 29300-132; 43063-505; 43063-912; 45865-541; 64330-054
UNII S62U433RMH
Synonyms zaleplon | 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide | N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide | L 846 | L-846 | Zelepion | Starnoc | SKP-1041 | CL 284,846 | CL-284846 | CL284,846 | CL 284846 | Sonata
Chemical Information
Molecular Formula C17H15N5O
CAS Registry Number 151319-34-5
SMILES CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethritis11.01.14.008; 20.07.02.001--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urine flow decreased20.02.02.012--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Paraesthesia oral17.02.06.008; 07.05.05.035--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Breast disorder21.05.04.004--Not Available
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Central nervous system stimulation25.04.01.001--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene